Estimating the global demand curve for a leishmaniasis vaccine: a generalisable approach based

2 on global burden of disease estimates

- 3 Sakshi Mohan¹, Paul Revill¹, Stefano Malvolti², Melissa Malhame², Mark Sculpher¹, Paul M. Kaye³
 - 1. Center for Health Economics (CHE), University of York, York, United Kingdom
 - 2. MMGH Consulting, Zurich, Switzerland
- 6 3. York Biomedical Research Institute, Hull York Medical School, University of York, York,
- 7 United Kingdom

1

4

5

8

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

9 Corresponding author: Sakshi Mohan; sakshi.mohan@york.ac.uk (ORCID iD: 0000-0002-1268-1769)

Abstract

Background

A pressing need exists to develop vaccines for neglected diseases, including leishmaniasis. However, the development of new vaccines is dependent on their value to two key players – vaccine developers and manufacturers who need to have confidence in the global demand in order to commit to research and production; and governments (or other international funders) who need to signal demand based on the potential public health benefits of the vaccine in their local context, as well as its affordability. A detailed global epidemiological analysis is rarely available before a vaccine enters a market due to lack of resources as well as insufficient global data necessary for such an analysis. Our study seeks to bridge this information gap by providing a generalisable approach to estimating the commercial and public health value of a vaccine in development relying primarily on publicly available Global Burden of Disease (GBD) data. This simplified approach is easily replicable and can be used to guide discussions and investments into vaccines and other health technologies where evidence constraints exist. The approach is demonstrated through the estimation of the demand curve for a future leishmaniasis vaccine.

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Methodology/Principal findings We project the ability to pay over the period 2030-2040 for a vaccine preventing cutaneous and visceral leishmaniasis (CL / VL), using an illustrative set of countries which account for most of the global disease burden. First, based on previous work on vaccine demand projections in these countries and CL / VL GBD-reported incidence rates, we project the potential long-term impact of the vaccine on disability-adjusted life years (DALYs) averted as a result of reduced incidence. Then, we apply an economic framework to our estimates to determine vaccine affordability based on the abilities to pay of governments and global funders, leading to estimates of the demand and market size. Based on our estimates, the maximum ability-to-pay of a leishmaniasis vaccine (per course, including delivery costs), given the current estimates of incidence and population at risk, is higher than \$5 for nearly half of the 24 countries considered, with a median value-based maximum price of \$4.4-\$5.3, and total demand of over 560 million courses. **Conclusion/Significance** Our results demonstrate that both the quantity of vaccines estimated to be required by the countries considered as well as their ability-to-pay could make a vaccine for leishmaniasis commercially attractive to potential manufacturers. The methodology used can be equally applied to other technology developments targeting health in developing countries. **Author summary** As of 2019, between 498,000 and 862,000 new cases of all forms of leishmaniasis were estimated to occur each year resulting in up to 18,700 deaths and up to 1.6 million DALYs lost. Given low treatment coverage, poor compliance and the emergence of drug resistance, challenges in sustaining vector control strategies and the ability of parasites to persist in animal reservoirs

independent of human infection, an effective vaccine could significantly reduce the health and economic burden of these diseases. However, commitment to the development of a new vaccine requires a market signal from governments and global funders who in turn require better estimates of the potential public health value of the vaccine. This study uses the development of a leishmaniasis vaccine as a case study to illustrate a generalizable approach to estimating the commercial and public health value of a technology relying primarily on publicly available GBD data. More specifically, by projecting the potential public health impact of the rollout of a leishmaniasis vaccine and translating this into monetary values based on the concept of health opportunity cost, we estimate the demand curve for such a vaccine for an 11-year period between 2030 and 2040. At an estimated global demand of over 560 million courses and a median value-based maximum price of \$4.4-\$5.3, our results demonstrate that both the quantity of vaccines estimated to be required by the countries considered as well as their ability-to-pay make the vaccine commercially attractive to potential manufacturers.

Introduction

According to the Global Burden of Disease (GBD) study 2019, between 498,000 and 862,000 new cases of all forms of leishmaniasis were estimated to occur each year resulting in up to 18,700 deaths and up to 1.6 million DALYs lost(1). Previously designated one of the most neglected among neglected tropical diseases (NTDs) based on limited resources invested in diagnosis, treatment and control(2), leishmaniasis accounts for 4% of the global DALY burden of NTDs and 5.5% of global NTD-related deaths. Furthermore, it is widely believed that these numbers grossly underestimate the real burden of leishmaniasis as a result of underreporting and limited understanding of the true lifetime impact of the disease(3–5).

The two most prevalent forms of leishmaniasis are localized cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). Despite the availability of effective treatment regimens, access to

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

treatment remains low(6,7). Given low treatment coverage, the occurrence of poor compliance and the emergence of drug resistance(8), challenges in sustaining vector control strategies(9), and the ability of parasites to persist in animal reservoirs, vaccines are widely regarded as having the potential to significantly impact the health burden posed by leishmaniasis and to contribute to regional leishmaniasis elimination campaigns (10). Between 2007 and 2013, nearly \$66 million was invested by public sector and philanthropic funders towards leishmaniasis vaccine research and development(11). Numerous vaccine candidates have been evaluated in preclinical models of disease, but few have progressed to clinical trial stage(11). Currently, only one therapeutic clinical trial is ongoing (12), and a genetically attenuated live L. major vaccine is due to be manufactured for use in a clinical trial in 2021(13,14). However, it is not enough just to develop a clinically effective vaccine. Rather, the vaccine also needs to be affordable and suitable for delivery and administration in health systems. In particular, for a vaccine to be produced and used, it needs to offer value to two key players: vaccine developers and manufacturers who need to have confidence in global demand in order to commit to research and production; and governments (or other international funders) who need to be sure of the potential public health benefits of the vaccine in their local context, as well as affordability of the vaccine, in order to signal demand. This study seeks to fill this information gap about the commercial value proposition and likely demand for a future leishmaniasis vaccine. This evaluation of a vaccine's potential economic value can also help shed light on key targets for vaccine development and manufacturing plans such as efficacy targets, target population groups/geographies, upper bound for manufacturing costs (and required scale of manufacturing), and target market size while the vaccine is under development.

More generally, this study seeks to develop a simplified and generalizable framework which employs publicly available burden of disease data to project the affordability, market size and public health value of new interventions in order to inform and spur continued product development that can improve health in low and middle-income countries (LMICs).

Methods

General approach

This study assesses the value associated with the introduction of a vaccine to prevent CL / VL. Value is assessed in terms of the vaccine's potential impact on mortality and morbidity taking into account its affordability within an illustrative set of countries in which the disease in endemic. First, based on previous work on vaccine demand projections in these countries(14) and CL / VL incidence rates(1), we project the potential long-term impact of a leishmaniasis vaccine on disability-adjusted life years (DALYs) averted as a result of reduced incidence. Ideally, such an analysis would require a detailed modeling of the disease epidemiology, disease dynamics, and health system capabilities of each country under consideration. However, such models are not currently available for most countries but planning for vaccine research and manufacturing needs to continue in their absence. Therefore, we sought to develop a simplified approach, which uses publicly available data on disease incidence and burden and population growth projections to assess the public health value of a future vaccine.

Second, we apply a health economic framework to our estimates of the future health impact of a vaccine to determine the vaccine's affordability based upon the abilities to pay of governments and global funders, leading to estimates of the demand and market size in this illustrative set of countries. All monetary values are presented in 2019 US Dollars (USD).

Geographic focus

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

The analysis in this paper is focused on a representative sample of 24 countries belonging to a range of income levels(15), geographic regions, type of endemic leishmaniasis, and Gavi, The Vaccine Alliance (GAVI) support status(16) (Table 1). In 2019, these countries together represented 80% of the global DALY burden of CL and VL, and 70% and 82% of the global incidence of CL and VL respectively (1). Vaccine efficacy and health effects In the absence of a rigorous epidemiological model, we project the health effect of a vaccine using the following estimates: i) total population susceptible to the disease (or population at risk); ii) incidence of the disease among the population at risk; iii) per person burden of disease; and iv) vaccine coverage and efficacy. This sub-section describes how these estimates were obtained and used. Environmental factors that affect the relationship between hosts, vectors (human, animal or sandfly) and the reservoir determine the risk of leishmaniasis in the population. Malvolti et al. (2021)(14) draw upon WHO Leishmaniasis country profiles as well as Pigott et al. (2014) (17) to project the size of the population at risk for leishmaniasis-endemic countries until 2040 using 5-year population growth projections from UN/DESA(18). The age-wise composition of the population at risk was based on projection from the World Population Prospects report(19). Incidence estimates were obtained from the Global Burden of Disease (GBD) study in 2019(1). These were converted into incidence rates specific to populations at risk for 2019 by dividing the incidence by the size of the population at risk (note that this assumes that no one outside the main population at risk contracts the disease) for the different age groups included in the vaccine demand projections in Malvolti et al. (2021)(14), namely 0-4 years, 5-14 years, and 15-29 years old. In the absence of epidemiological projections of leishmaniasis incidence and given that there has not been a

significant decline in incidence over the last five years (20), we make the assumption that the incidence rate among the population at risk remains constant between 2019 and 2040. Note that for countries with anthroponotic VL transmission (i.e. Bangladesh, India, Nepal, Somalia, South Sudan and Sudan), where VL is projected to be eliminated by Malvolti et al. (2021) (14) through existing measures and deployment of a vaccine, we assume that in the absence of vaccine introduction, the population at risk would continue to grow at the 5-year population growth rate from UN/DESA(18). Similarly, the per person DALY burden of the disease was obtained from the 2019 GBD study for each country and age group considered by dividing the relevant total DALY burden by the incidence, given that the average duration of both CL and VL is less than a year(21). The 2019 values of the epidemiological parameters used are shown in Table 2. This approach was taken due to the lack of country-level data on the per-case DALY burden of the disease. We considered it important to use country-level estimates due to the disparity between countries(2) in terms of clinical and epidemiological presentations, comorbidities, treatment coverage, and fatality rates. Based on previously developed vaccines(22), efficacy was assumed to be 75% in the base case (based on the efficacy of previously researched leishmanization methods(22,23)). However, an efficacy range between 50% and 95% is considered under sensitivity analysis. The duration of the efficacy was assumed to be 10 years and an annual discount rate of three percent applied to health gains in the future.

Quantity of vaccines demanded

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

Quantity demanded or demand here refers to the total vaccines projected to be required by a country in a given year based on the target population at risk and rollout constraints, regardless of market price. The vaccine demand projections are based on Malvolti et al. (2021)(14). This assumed a dual vaccine delivery strategy, including a catch-up campaign at the start followed by rollout in a

routine immunization program. Routine immunization includes two age groups - 0-4 years, and 5-14 years. The catch-up campaign for CL includes two groups - 5-14 years, and 15-29 years; and for VL only the 5-14 years age group was assumed to be targeted. Coverage estimates (those vaccinated as a percentage of those targeted) are based on current vaccines with similar vaccination rollout strategies (see Malvolti et al (2021)(14) for details). Country-wise vaccine demand projections by age are provided in **Supplementary table 1**.

Health economic analysis – global demand for a leishmaniasis vaccine

We assume that a heath intervention should be provided if it produces more health than could be generated elsewhere in the health care system with the same resources (i.e. the benefits exceed the opportunity costs). For every DALY averted (or QALY gained) from a new intervention, a health system should pay no more than the cost at the margin at which it is already able to avert a DALY from existing interventions (i.e. the marginal productivity; sometimes estimated as a cost-effectiveness threshold (CET)). This approach, previously applied in country-specific studies(24,25), allows us to estimate the maximum ability-to-pay, or the value-based maximum price, for a leishmaniasis vaccine with a given efficacy. A country would demand the required number of courses of the vaccine(14) if the price offered by the manufacturer is below their value-based maximum price, and none if the global market price is above their value-based maximum price. Note that our ability to pay estimates are inclusive of implementation costs incurred for the rollout of the vaccine, i.e. the ability to pay for the medical product itself can be calculated by countries by subtracting their local implementation costs from our estimates.

To determine a price at which a country can afford the hypothetical vaccine requires an estimate of the CET to reflect marginal productivity. We use the 'health budget opportunity cost' approach(26) for CET estimates. A country government may choose to fund the vaccine only if it generates more health than that which would be forgone if its limited health budget is redirected from existing

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

interventions to the vaccine. Country-level CETs have previously been estimated until 2040 by Lomas et al. (2021)(27) based on historical estimates (28) of the marginal productivity of the different countries' health systems. For countries for which these estimates were missing, CETs were projected as an appropriate percentage of the projected GDP per capita(29) based on Ochalek et al. (2020)(30). Country-level CET estimates used here are provided in Supplementary table 2. In addition to averting DALYs through reduced infections, the vaccine would also reduce system treatment costs which in turn would indirectly increase the ability to pay for the vaccine. The actual reduction in treatment costs for the infected population depends on the expected coverage of treatment, which in most countries would be less than 100%. In the absence of data on leishmaniasis treatment coverage, we project the value-based maximum price under the assumptions of both 0% and 100% treatment coverage to represent its upper and lower bounds. We assume an average treatment cost per VL case of \$541 based on Carvalho et al. (2017) (31). This estimate includes the average cost through the lifecycle of treatment including pre-diagnosis consultation, drug therapy, hospitalization and ambulatory care until post-treatment consultations. Note that the drug therapy costs are based on the proportion of VL cases treated with meglumine antimoniate, liposomal amphotericin B or amphotericin B deoxycholate respectively in Brazil in 2014. The average treatment cost per CL case is assumed to be \$57.6 based on Rodriguez et al. (2019)(32). This estimate is based on the cost of the drug used (Intralesional pentavalent antimonials (ILPA)) and staff time costs for CL treatment in Bolivia. Using these concepts, we were able to calculate the value-based maximum price for a course of the leishmaniasis vaccine that each country is able to pay during each year of rollout, given the potential health benefit provided by the vaccine, and the country's CET (Box 1, equation 1). The demand for vaccines for both CL and VL prevention and the ability-to-pay for each target use case (CL prevention

and VL prevention) are aggregated to derive each country's global ability-to-pay for the vaccine (Box 1, equation 3).

Combined with the vaccine courses estimated to be required for each country, these are used to construct global demand curves for the vaccine during the 11-year period between 2030 and 2040. For this purpose, we estimate the average value-based maximum price over 11 years, by dividing the sum of the maximum resources which could be committed towards the leishmaniasis vaccine during each year (price times demand) by the aggregate demand between 2030 and 2040.

Box 1: Equations to estimate countries abilities to pay for a leishmaniasis vaccine

The value-based maximum price or ability-to-pay for a course of a leishmaniasis vaccine that each country is able to pay is estimated using the following formula:

$$p_{i,t,\alpha} = \frac{CET_{i,t} \Delta DALY_{i,t,\alpha} + \Delta T_{i,t,\alpha}}{q_{i,t,\alpha}},$$
(1)

$$\begin{split} \Delta DALY_{i,t,\alpha} &= \sum_{\beta} \left[\Delta I_{i,t,\alpha,\beta} \ \sum_{n=0}^{N} \frac{\Delta DALY_pp_{i,\alpha,\beta}}{(1+r)^{n}} \right] \\ \Delta T_{i,t,\alpha} &= \ \theta \ \sum_{n=0}^{N} \frac{\Delta I_{i,t,\alpha} \ T_pp_{\alpha}}{(1+r)^{n}} \end{split}$$

$$\alpha = \{CL, VL\}$$

Where i = country

231

232

233

234

235

236

237

238

239

t = year of vaccination

 β = age groups— 0-4 years, 5-14 years, 15-29 years

perpetuity.

It is made available under a CC-BY 4.0 International license .

n = year of vaccine efficacy

N = Number of years for which the vaccine is effective

r = annual discount rate

p = Value-based price for a course of the vaccine

CET = Cost-effectiveness threshold (\$/DALY averted)

△DALY = Total DALYs averted from the reduction in CL-related/VL-related mortality

△DALY_pp = Change in DALYs per person infected with CL/VL

I = Change in CL/VL incidence as a result of the administration of the vaccine

T = Direct treatment cost of CL/VL

T_pp = Direct treatment cost per case of CL/VL

q = demand for the vaccine

 θ = coverage of leishmaniasis (CL and VL) treatment

To obtain the aggregate demand curve for the period 2030-2040, we obtain the aggregate demand for vaccine courses and the average value-based maximum price for each country across the target use cases as follows:

$$Q_i = \sum_{\alpha} \sum_{t} q_{i,t,\alpha} \tag{2}$$

$$\bar{p}_i = \frac{\sum_{\alpha} \sum_{t} p_{i,t,\alpha} \ q_{i,t,\alpha}}{Q_i} \tag{3}$$

Where

240

241

 Q_i = country i's aggregate demand for the vaccine between 2030 and 2040

 $ar{p}_i$ = Average value-based price for a course of the vaccine for country i for the period under consideration

Sensitivity Analysis

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

We evaluate the sensitivity of the projected global demand curves to three factors - i) vaccine efficacy, ii) contributions from GAVI, and iii) adjustment for underreporting of leishmaniasis incidence. Under the first sensitivity analysis, the value-based maximum prices and global demand curves are reevaluated for vaccine efficacy rates of 50% and 95%. Sensitivity analysis is also carried out to assess the effect on global demand curves with GAVI contribution towards countries which are expected to be eligible for support between 2030 and 2040 based on GDP per capita projections(29) using GAVI's criterion for support as of 2019(16). We assume that a country is eligible for GAVI support during the 11 years under consideration if its projected GDP per capita between 2026 and 2028 is under \$1580 (i.e. the country is either in the initial self-financing or preparatory transition phase) or if its GDP per capita has been greater than \$1580 for 5 years or less between 2022 and 2028 (i.e. the country is in the accelerated transition phase). Given GAVI's current portfolio of vaccines, we expect GAVI's maximum ability to pay for vaccines to be higher than that of some of the countries eligible for support. Based on previous work on GAVI's willingness to pay for the rotavirus vaccine(33), we assume GAVI's cost effectiveness threshold to be \$285 in 2019 USD. Therefore, under this sensitivity analysis, we re-estimate the demand curve for a leishmaniasis vaccine by increasing the CET value for countries eligible for GAVI support to \$285 if their own CET is lower in a given year. Country-level GAVI support projections are provided in Supplementary table 3. Finally, we also assess the potential effect of adjusting for the underreporting of cases on the valuebased maximum price, using estimates from Alvar et al. (2012)(34) of CL and VL underreporting by factors in the ranges 3.2-5.7 and 3.5-6.7 respectively (globally).

Results

Calculation of value-based maximum price

We calculated the country-wise value-based maximum price per course of the leishmaniasis vaccine and total demand based on equations 1,2 and 3, presented in tabular format (**Table 3**) and in the form of a demand curve for the illustrative set of 24 countries (**Figure 1**). As expected, the median value-based maximum price under the assumption of full coverage of CL and VL treatment is higher (by 19% on average) than under the assumption of no provision of treatment. This is because any treatment expenses saved through reduced incidence increase a country's ability to pay for the vaccine. The median value-based maximum price for the illustrative set of countries is \$4.4 and \$5.3 under the assumption of 0% and 100% treatment coverage respectively.

Sensitivity analysis

2030 and 2040>

Sensitivity to vaccine efficacy

The estimated prices in the above scenario assume a vaccine efficacy of 75% in preventing CL / VL. Since vaccines against leishmaniasis are still under development or under testing, the actual efficacy is unknown. We therefore also consider the effect of a change in vaccine efficacy on value-based maximum prices (Figure 2). At an efficacy of 95%, the vaccine would prevent a larger number of cases of CL / VL, averting more DALYs, and allowing countries to be able to pay a higher price at the margin per course. This shifts the demand curve upwards from the earlier scenario assuming 75% efficacy. Similarly, a lower efficacy of 50% shifts the demand curve downwards. More specifically, the median value-based maximum price falls from \$4.4 to \$3.4 under the assumption of 0% treatment coverage and from \$5.3 to \$3.8 under the assumption of 100% treatment coverage when

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

the efficacy falls from 75% to 50%. At 95% efficacy, the median values rise to \$5.5 and \$6.5 respectively (Table 4). < Figure 2: Sensitivity of value-based maximum price to vaccine efficacy: (i) assuming treatment coverage = 0%, (ii) assuming treatment coverage = 100%> Impact of GAVI support for vaccine introduction The results described above treat countries as independent buyers of the vaccine whose ability to pay per vaccine course depends on their respective CET. However, international donors are often able to ensure the expansion of important health interventions to low and lower-middle income countries even when these may be locally cost-ineffective as a result of budget constraints. We consider the effect of future GAVI funding of a potential leishmaniasis vaccine for countries eligible for its support based on current criteria(16). We project that 11 of the 24 countries in our illustrative list will be in one of the GAVI support phases (Supplementary table 3), of which six countries have a CET lower than \$285 in 2030. Using a CET of \$285/DALY averted for these six countries, provides an alternate demand curve (Figure 3). The mean value-based price nearly doubles under both treatment coverage scenarios (Table 4). <Figure 3: Illustrative global demand curve for a leishmaniasis vaccine (with 75% efficacy) between 2030 and 2040 including GAVI support> Sensitivity to underreporting The final sensitivity analysis adjusting for underreporting increases the median ability to pay to \$14.9 - \$18.2 under the assumption of underreporting by a factor of 3.2 and 3.5 for CL and VL, respectively. These figures increase to \$27.4 - \$33.4 when the upper bound underreporting factors of 5.7 and 6.7 are applied for CL and VL respectively (Figure 4, Table 4). <Figure 4: Sensitivity of value-based maximum price to underreporting: (i) Low underreporting</p> estimate, (ii) High underreporting estimate>

Discussion

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

This study has sought to provide a generalizable approach to estimating the commercial and public health value of new technologies in development relying primarily on publicly available GBD data. This simplified approach is easily replicable and can be used to guide discussions and investments into health technology development, particularly in low and middle-income countries (LMICs), which face significant constraints in acquiring and generating evidence compared with higher-income countries. The utility of this approach is demonstrated by projecting the economic feasibility of a leishmaniasis vaccine based on currently available estimates of cost-effectiveness thresholds based on marginal productivity, disease incidence and burden of disease. While other studies have previously tried to estimate the cost-effectiveness of vaccines (35,36) and the monetary value of health technologies (24,25), our approach is novel for its global focus and simplicity as well as the incorporation of practical considerations including a realistic timescale of when the product is expected to be available for distribution, gradual rollout and an evolving expected marginal productivity of health systems. Our results demonstrate that both the quantity of vaccines estimated to be required by the countries considered, which represent a majority of the global burden of disease from leishmaniasis, as well as their ability-to-pay make the vaccine commercially attractive to potential manufacturers. The global demand stands at over 560 million courses, and the value-based maximum price per course, given the current estimates of incidence and population at risk, is higher than \$5 for nearly half of the 24 countries considered. Assuming a full course of two doses and an expected manufacturing cost of \$2-3 per dose, based on adenovirus vaccines (37) similar to ChAd63-KH (the only leishmaniasis vaccine currently recruiting into clinical trial(12)), a leishmaniasis vaccine of this type would be commercially viable. The wide range of value-based maximum prices across different

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

countries also presents an opportunity for differential pricing to secure wide access. With possible future contributions from GAVI considering its current willingness to pay for the rotavirus vaccine(33), we estimate that the global demand curve would move further upwards. A similar upward effect in abilities to pay is observed with adjustment for underreporting. It should be noted that the prices presented above represent the maximum full health system cost per vaccinated individual that countries can afford in the future. In other words, in order to determine the value-based maximum price for the vaccine itself, countries will also need to consider the number of doses required per course as well as the implementation costs. We have not included implementation costs in our calculations because of the vast uncertainty in these costs and variability across settings(38). These costs could make the vaccine unaffordable for some countries. Furthermore, the quality of the underlying data on disease demographics, burden of disease, vaccine rollout projections as well as the lack of treatment coverage data impose uncertainty around our results. However, we believe that overall our projections underestimate the ability to pay for a leishmaniasis vaccine for a range of reasons including the exclusion of post-kala-azar dermal leishmaniasis (PKDL) and its effect on VL transmission (39), exclusion of disease dynamics or transmission effects, exclusion of psychosocial and mental health effects of the disease (which could amount to six times the current estimate of DALY burden for CL (40)), and exclusion of treatment cost for leishmaniasis-HIV coinfection (which would increase the treatment cost per VL case by up to four times (31)). Updating our assumptions based on a combination of all these factors could increase our estimates of maximum ability to pay. However, there are several other sources of uncertainty, imposed by a continuously evolving health sector landscape, which can only be addressed by updating these estimates as and when updated information becomes available. Therefore, our demand and price projections are far from definite but shine a light on important data gaps and uncertainties in

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

characterizing the leishmaniasis epidemic, addressing which will be crucial to better understanding the future value of a vaccine against these diseases. With better data, a full epidemiological model capturing disease dynamics should form the basis of projections of the public health value of potential technologies. Such analysis is rarely feasible before a product enters a market due to lack of resources as well as global data on necessary parameters. Our framework overcomes these challenges, albeit through various simplifications, and we suggest that our results can be used to guide investments into improving the data available on leishmaniasis. In addition, our results should help set in motion global discussions on the public health value and commitment towards a leishmaniasis vaccine and help direct vaccine target product profiles to ensure economic feasibility. References 1. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2019 (GBD 2019) Data Resources [Internet]. IHME. 2020 [cited 2021 Apr 1]. Available from: http://ghdx.healthdata.org/gbd-2019 2. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis [Internet]. Vol. 2, PLoS Neglected Tropical Diseases. PLoS Negl Trop Dis; 2008 [cited 2021 Apr 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/18958165/ 3. Bailey F, Mondragon-Shem K, Hotez P, Ruiz-Postigo JA, Al-Salem W, Acosta-Serrano Á, et al. A new perspective on cutaneous leishmaniasis—Implications for global prevalence and burden of disease estimates. PLoS Negl Trop Dis. 2017;11(8):2-6. 4. Bailey F, Mondragon-Shem K, Haines LR, Olabi A, Alorfi A, Ruiz-Postigo JA, et al. Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates. Boelaert M, editor. PLoS Negl Trop Dis [Internet]. 2019 Feb 25 [cited 2021 Apr 9];13(2):e0007092. Available from: https://dx.plos.org/10.1371/journal.pntd.0007092

396 5. Singh VP, Ranjan A, Topno RK, Verma RB, Siddique NA, Ravidas VN, et al. Short report: 397 Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am J Trop Med 398 Hyg [Internet]. 2010 Jan [cited 2021 Mar 26];82(1):9–11. Available from: 399 /pmc/articles/PMC2803501/ 400 6. den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. Vol. 17, 401 Clinical Microbiology and Infection. Blackwell Publishing Ltd; 2011. p. 1471–7. 402 7. Pascual Martínez F, Picado A, Roddy P, Palma P. Low castes have poor access to visceral 403 leishmaniasis treatment in Bihar, India. Trop Med Int Heal [Internet]. 2012 May 1 [cited 2021 404 Jul 1];17(5):666–73. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-405 3156.2012.02960.x 406 8. Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. Vol. 9, Asian Pacific Journal of 407 Tropical Medicine. Elsevier (Singapore) Pte Ltd; 2016. p. 925–32. 408 9. Dantas-Torres F, Brandão-Filho SP. Visceral leishmaniasis in Brazil: Revisiting paradigms of 409 epidemiology and control. Vol. 48, Revista do Instituto de Medicina Tropical de Sao Paulo. 410 2006. p. 151-6. 411 10. Kamhawi S. The yin and yang of leishmaniasis control. Aksoy S, editor. PLoS Negl Trop Dis 412 [Internet]. 2017 Apr 20 [cited 2021 Apr 12];11(4):e0005529. Available from: 413 https://dx.plos.org/10.1371/journal.pntd.0005529 414 11. Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME. Status of vaccine 415 research and development of vaccines for leishmaniasis. Vaccine. 2016 Jun 3;34(26):2992-5. 416 Kaye P. A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine 12. 417 ChAd63-KH in PKDL [Internet]. ClinicalTrials.gov Identifier: NCT03969134. 2019 [cited 2021 Jul 418 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03969134 419 Zhang WW, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N, et al. A second 13. 420 generation leishmanization vaccine with a markerless attenuated Leishmania major strain 421 using CRISPR gene editing. Nat Commun. 2020;11(1):1-14.

422 14. Malvolti S, Malhame M, Mantel C, Rutte EA Le, Kaye PM. Human leishmaniasis vaccines: use 423 cases, target population and potential global demand. PLoS Negl Trop Dis. 2021; Forthcoming. 424 The World Bank. New country classifications by income level: 2019-2020 [Internet]. World 15. 425 Bank Blogs. 2019 [cited 2021 Apr 12]. Available from: 426 https://blogs.worldbank.org/opendata/new-country-classifications-income-level-2019-2020 427 16. GAVI. How to request new GAVI support. Geneva; 2019. 428 Pigott DM, Bhatt S, Golding N, Duda KA, Battle KE, Brady OJ, et al. Global distribution maps of 17. 429 the Leishmaniases. Elife. 2014 Jun 27;2014(3). 430 18. Nations U, of Economic D, Affairs S, Division P. World Population Prospects 2019, Volume I: 431 Comprehensive Tables. 432 19. Nations U, of Economic D, Affairs S, Division P. World Population Prospects 2019, Volume II: 433 Demographic Profiles [Internet]. 2019 [cited 2021 Apr 1]. Available from: 434 www.unpopulation.org. 435 Abbafati C, Machado DB, Cislaghi B, Salman OM, Karanikolos M, McKee M, et al. Global age-20. 436 sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 437 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the 438 Global Burden of Disease Study 2019. Lancet [Internet]. 2020 Oct 17 [cited 2021 Apr 439 1];396(10258):1160-203. Available from: http://www. 440 21. Heydarpour F, Sari AA, Mohebali M, Shirzadi M, Bokaie S. Incidence and Disability-Adjusted 441 Life Years (Dalys) Attributable to Leishmaniasis In Iran, 2013. Ethiop J Health Sci [Internet]. 442 2016 Jul 1 [cited 2021 Apr 7];26(4):381–8. Available from: /pmc/articles/PMC4992778/ 443 22. Cecílio P, Oliveira F, Silva AC da. Vaccines for Human Leishmaniasis: Where Do We Stand and 444 What Is Still Missing? In: Leishmaniases as Re-emerging Diseases. InTech; 2018. p. 59–79. 445 Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, Gicheru MM. Development of 23. 446 Leishmania vaccines: predicting the future from past and present experience. J Biomed Res 447 [Internet]. 2013 [cited 2021 Aug 13];27(2):85. Available from: /pmc/articles/PMC3602867/

448 24. Phillips AN, Cambiano V, Nakagawa F, Ford D, Apollo T, Murungu J, et al. Point-of-Care Viral 449 Load Testing for Sub-Saharan Africa: Informing a Target Product Profile. Open Forum Infect 450 Dis [Internet]. 2016 May 1 [cited 2021 Aug 19];3(3). Available from: 451 https://academic.oup.com/ofid/article/3/3/ofw161/2593307 452 25. Cambiano V, Ford D, Mabugu T, Napierala Mavedzenge S, Miners A, Mugurungi O, et al. 453 Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-454 Income Countries. J Infect Dis [Internet]. 2015 Aug 15 [cited 2021 Aug 19];212(4):570-7. 455 Available from: https://academic.oup.com/jid/article/212/4/570/818811 456 26. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-457 income countries: A novel approach and evidence from cross-country data. BMJ Glob Heal 458 [Internet]. 2018 Jan 1 [cited 2020 Jul 16];3(6):964. Available from: 459 http://dx.doi.org/10.1136/bmjgh-2018-000964 460 27. Lomas J, Claxton K, Ochalek J. Accounting for country- and time-specific values in the 461 economic evaluation of health-related projects relevant to low- and middle-income 462 countries. Health Policy Plan. 2021; Forthcoming. 463 28. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-464 income countries: a novel approach and evidence from cross-country data. BMJ Glob Heal 465 [Internet]. 2018 [cited 2020 Jan 6];3:964. Available from: http://dx.doi.org/10.1136/bmjgh-466 2018-000964 467 29. Micah AE, Su Y, Bachmeier SD, Chapin A, Cogswell IE, Crosby SW, et al. Health sector 468 spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance 469 for health: progress towards Sustainable Development Goal 3. Lancet [Internet]. 2020 Apr 470 [cited 2020 Jul 23];0(0). Available from: https://doi.org/10.1016/S0140-6736 471 30. Ochalek J, Claxton K, Lomas J, Thompson KM. Valuing health outcomes: developing better 472 defaults based on health opportunity costs. https://doi.org/101080/1473716720201812387 473 [Internet]. 2020 [cited 2021 Aug 8]; Available from:

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

https://www.tandfonline.com/doi/abs/10.1080/14737167.2020.1812387 31. de Carvalho IPSF, Peixoto HM, Romero GAS, de Oliveira MRF. Cost of visceral leishmaniasis care in Brazil. Trop Med Int Heal [Internet]. 2017 Dec 1 [cited 2021 Apr 7];22(12):1579-89. Available from: http://doi.wiley.com/10.1111/tmi.12994 Eid Rodríguez D, San Sebastian M, Pulkki-Brännström A-M. "Cheaper and better": Societal 32. cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia. Al-Salem WS, editor. PLoS Negl Trop Dis [Internet]. 2019 Nov 6 [cited 2021 Apr 7];13(11):e0007788. Available from: https://dx.plos.org/10.1371/journal.pntd.0007788 33. Debellut F, Clark A, Pecenka C, Tate J, Baral R, Sanderson C, et al. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. Lancet Glob Heal. 2019 Dec 1;7(12):e1664-74. 34. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence [Internet]. Vol. 7, PLoS ONE. Public Library of Science; 2012 [cited 2021 Jul 1]. p. 35671. Available from: www.plosone.org 35. Ochalek J, Abbas K, Claxton K, Jit M, Lomas J. Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. BMJ Glob Heal [Internet]. 2020 Oct 20 [cited 2021 Mar 26];5(10):3006. Available from: http://dx.doi.org/10.1136/bmjgh-2020-003006 36. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB. The economic value of a visceral leishmaniasis vaccine in Bihar State, India. Am J Trop Med Hyg [Internet]. 2012 Mar [cited 2021 Mar 26];86(3):417–25. Available from: /pmc/articles/PMC3284356/ 37. Biopharm. COVID-19 Adenovirus-Based Vaccine Supply – Production Titre & Dosage Quantity will be Critical to Achieve Global Access [Internet]. 2020 [cited 2021 Apr 8]. Available from: https://www.biopharmservices.com/covid-19-adenovirus-based-vaccine-supply-productiontitre-dosage-quantity-will-be-critical-to-achieve-global-access/

500 Portnoy A, Vaughan K, Clarke-Deelder E, Suharlim C, Resch SC, Brenzel L, et al. Producing 38. 501 Standardized Country-Level Immunization Delivery Unit Cost Estimates. Pharmacoeconomics 502 [Internet]. 2020 Sep 1 [cited 2021 Apr 12];38(9):995–1005. Available from: 503 https://doi.org/10.1007/s40273-020-00930-6 504 39. Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M. Post kala-azar dermal leishmaniasis: An 505 unresolved mystery [Internet]. Vol. 30, Trends in Parasitology. Elsevier; 2014 [cited 2021 Apr 506 9]. p. 65-74. Available from: /pmc/articles/PMC3919212/ 507 40. Bailey F, Mondragon-Shem K, Haines LR, Olabi A, Alorfi A, Ruiz-Postigo JA, et al. Cutaneous 508 leishmaniasis and co-morbid major depressive disorder: A systematic review with burden 509 estimates. Boelaert M, editor. PLoS Negl Trop Dis [Internet]. 2019 Feb 25 [cited 2020 May 510 8];13(2):e0007092. Available from: http://dx.plos.org/10.1371/journal.pntd.0007092 511

		WHO	World Bank	Disease	GAVI support status
Country	Continent	Region	Income Level	endemicity	(2020)
Afghanistan	Asia	EMRO	Upper-middle	VL	Initial self-financing
Algeria	Africa	EMRO	Upper-middle	VL	Ineligible
Bangladesh	Asia	SEARO	Low	CL & VL	Preparatory transition
Brazil	South America	РАНО	Upper-middle	VL	Ineligible
China	Asia	WPRO	Lower-middle	CL & VL	Ineligible
Ethiopia	Africa	AFRO	High	CL	Initial self-financing
Georgia	Europe	EURO	Lower-middle	VL	Fully self-financing
India	Asia	SEARO	Lower-middle	CL	Accelerated transition
Israel	Asia	EURO	Lower-middle	VL	Ineligible
Kenya	Africa	AFRO	Lower-middle	CL	Preparatory transition
Morocco	Africa	EMRO	Lower-middle	CL	Ineligible
Nepal	Asia	SEARO	Upper-middle	VL	Initial self-financing
Nigeria	Africa	AFRO	High	CL	Accelerated transition

Pakistan	Asia	EMRO	Low	VL	Preparatory transition
Paraguay	South America	РАНО	Low	VL	Ineligible
Saudi Arabia	Asia	EMRO	High	VL	Ineligible
Somalia	Africa	EMRO	Low	CL & VL	Initial self-financing
South Sudan	Africa	EMRO	Low	CL	Initial self-financing
Spain	Europe	EURO	Lower-middle	CL	Ineligible
Sudan	Africa	AFRO	Upper-middle	CL	Preparatory transition
Syria	Asia	EMRO	Lower-middle	CL	Initial self-financing
Tunisia	Africa	EMRO	Upper-middle	VL	Ineligible
Turkey	Asia	EURO	Upper-middle	VL	Ineligible
Uzbekistan	Asia	EURO	Low	CL & VL	Accelerated transition

Table 2: Epidemiological parameters (2019)

			Visceral Le	ishmaniasis						Cutaneous L	eishmaniasis.			
Country	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYs lost per perso n (15- 19 years)	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYs lost per perso n (15- 19 years)
Afghanistan	-				7.24	5.25	7.12	11,124,437	0.944%	2.129%	1.374%	0.17	0.42	1.30
Algeria	-				8.31	5.08	6.44	10,609,819	0.187%	0.383%	0.275%	0.03	0.03	0.03
Bangladesh	30,955,876	0.003%	0.002%	0.001%	16.32	10.40	13.77	-						
Brazil	82,117,821	0.020%	0.015%	0.005%	14.40	10.02	14.86	-				0.04	0.04	0.04
China	232,875,38	0.001%	0.001%	0.000%	0.02	0.02	0.02	-				0.03	0.04	0.09
Ethiopia	3,424,788	0.123%	0.099%	0.035%	23.72	17.04	17.28	5,455,824	0.002%	0.003%	0.002%	0.17	0.52	1.78
Georgia	2,580,002	0.009%	0.007%	0.002%	8.77	3.68	5.50	-				0.03	0.03	0.03

			Visceral Le	ishmaniasis						Cutaneous L	eishmaniasis			
Country	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYs lost per perso n (15- 19 years)	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	per perso n (15-19 years)
India	134,094,34 7	0.017%	0.014%	0.004%	11.92	6.93	11.57	107,275,47	0.000%	0.000%	0.000%	0.12	0.45	1.24
Israel	-				7.06	4.04	5.80	8,971,638	0.002%	0.004%	0.004%	0.03	0.03	0.03
Kenya	3,501,646	0.075%	0.053%	0.018%	10.48	12.26	16.09	-				0.11	0.22	0.46
Morocco	-				6.44	5.31	6.72	6,364,300	0.134%	0.251%	0.149%	0.11	0.27	0.59
Nepal	29,942,425	0.002%	0.002%	0.001%	11.30	7.70	11.76	-						
Nigeria	-				26.32	17.98	13.73	3,238,811	0.000%	0.000%	0.001%	0.20	0.57	1.41
Pakistan	-				11.75	9.17	14.55	91,841,655	0.011%	0.021%	0.017%	0.14	0.40	1.29
Paraguay	3,180,239	0.004%	0.003%	0.001%	15.33	12.35	16.40	-				0.08	0.13	0.17
Saudi Arabia	-				8.70	4.34	5.94	3,794,820	0.028%	0.208%	0.343%	0.03	0.03	0.03

			Visceral Le	ishmaniasis						Cutaneous I	eishmaniasis.			
Country	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYS lost per perso n (5- 14 years)	DALYS lost per perso n (15- 19 years)	Population at risk	Incidence (%) among populatio n at risk (0-4 years)	Incidence (%) among populatio n at risk (5-14 years)	Incidence (%) among populatio n at risk (15-19 years)	DALYs lost per perso n (0-4 years)	DALYs lost per perso n (5- 14 years)	DALYS lost per perso n (15- 19 years)
Somalia	2,585,353	0.104%	0.080%	0.028%	17.72	16.24	15.52	-						
South Sudan	2,088,706	0.432%	0.345%	0.103%	21.24	14.36	13.96	-						
Spain	37,193,165	0.001%	0.000%	0.000%	7.12	4.27	5.99	-				0.03	0.03	0.03
Sudan	9,336,300	0.084%	0.068%	0.025%	7.37	4.40	6.54	40,171,954	0.004%	0.010%	0.008%	0.12	0.26	0.78
Syria	-				8.16	6.06	6.76	18,192,904	0.276%	0.911%	0.574%	0.08	0.12	0.16
Tunisia	-				7.36	4.41	6.03	6,220,910	0.184%	0.446%	0.283%	0.03	0.03	0.03
Turkey	-				8.97	4.96	5.86	43,467,592	0.015%	0.023%	0.013%	0.03	0.03	0.03
Uzbekistan	-				8.29	4.23	5.33	16,236,757	0.017%	0.021%	0.016%	0.03	0.03	0.03

	Total demand for	Value-based maximum	Value-based maximum price
Country	vaccine courses (2030-	price per course (assuming	per course (assuming
	2040)	treatment coverage = 0%)	treatment coverage = 100%)
Afghanistan	12,963,289.41	7.25	13.41
Algeria	9,167,695.55	4.67	5.87
Bangladesh	11,450,264.05	1.81	2.03
Brazil	33,953,582.53	113.71	114.30
China	76,399,800.95	0.02	0.05
Ethiopia	9,532,973.75	24.16	25.36
Georgia	936,403.91	4.00	4.27
India	135,475,311.59	6.60	7.09
Israel	8,893,083.19	0.46	0.48
Kenya	3,369,092.01	41.74	43.89
Morocco	4,878,091.63	8.33	9.08
Nepal	11,517,484.52	1.45	1.64
Nigeria	5,015,541.10	0.01	0.01

Pakistan	101,103,820.38	0.18	0.25
Paraguay	2,078,491.89	29.23	29.36
Saudi Arabia	3,125,074.95	11.57	12.36
Somalia	1,585,208.80	8.65	19.82
South Sudan	1,049,268.43	115.09	159.44
Spain	10,171,505.03	5.55	5.57
Sudan	55,713,341.93	4.22	5.02
Syria	21,633,241.88	1.31	3.93
Tunisia	4,447,800.09	3.42	4.73
Turkey	23,864,258.55	0.83	0.90
Uzbekistan	15,730,232.81	0.09	0.16
	Median	4.44	5.29
	Mean	16.43	19.54

Table 4: Value-based maximum price for a leishmaniasis vaccine course (2030-2040) – Sensitivity analyses

	Wi	th GAVI support		Efficacy = 50%		Efficacy = 95%	factor o	Underreporting by a factor of 3.2 (CL) and 3.5 (VL)		Underreporting by a factor of 5.7 (CL) and 6.7 (VL)	
Country	VBP (assuming treatment coverage = 0%)	VBP (assuming treatment coverage = 100%)	VBP (assuming treatment coverage = 0%)	VBP (assuming treatment coverage = 100%)	VBP (assuming treatment coverage 0%)	t treatment	VBP (assuming treatment coverage = 0%)	VBP (assuming treatment coverage = 100%)	VBP (assuming treatment coverage = 0%)	VBP (assuming treatment coverage = 100%)	
Afghanistan	19.39	25.56	19.39	25.56	9.18	16.99	23.39	43.30	41.08	76.05	
Algeria	4.67	5.87	4.67	5.87	5.92	7.44	15.08	18.96	26.48	33.30	
Bangladesh	1.81	2.03	1.81	2.03	1.98	2.23	6.29	7.06	12.11	13.58	
Brazil	113.71	114.30	113.71	114.30	144.03	144.78	394.86	396.91	759.85	763.79	
China	0.02	0.05	0.02	0.05	0.02	0.07	0.06	0.19	0.12	0.37	
Ethiopia	24.16	25.36	24.16	25.36	30.60	32.12	83.89	88.06	161.40	169.42	
Georgia	4.00	4.27	4.00	4.27	5.07	5.41	13.89	14.82	26.73	28.52	
India	6.60	7.09	6.60	7.09	7.20	7.74	22.93	24.61	44.12	47.35	
Israel	0.46	0.48	0.46	0.48	0.59	0.60	1.50	1.54	2.63	2.71	
Kenya	41.74	43.89	41.74	43.89	52.88	55.60	144.96	152.42	278.95	293.31	
Morocco	8.33	9.08	8.33	9.08	10.55	11.50	26.90	29.30	47.23	51.46	
Nepal	1.45	1.64	1.45	1.64	1.59	1.80	5.05	5.69	9.71	10.95	

Mean	32.54	35.65	12.31	14.94	19.73	23.22	56.67	67.34	108.19	128.42
Median	4.44	5.29	3.41	3.81	5.49	6.52	14.85	18.18	27.41	33.36
Uzbekistan	0.09	0.16	0.09	0.16	0.11	0.20	0.28	0.51	0.50	0.90
Turkey	0.83	0.90	0.83	0.90	1.05	1.14	2.67	2.90	4.69	5.09
Tunisia	3.42	4.73	3.42	4.73	4.33	5.99	11.04	15.27	19.39	26.81
Syria	1.63	4.24	1.63	4.24	1.66	4.97	4.23	12.68	7.43	22.26
Sudan	4.22	5.02	4.22	5.02	4.60	5.48	14.63	17.40	28.10	33.42
Spain	5.55	5.57	5.55	5.57	7.03	7.05	19.28	19.33	37.10	37.20
South Sudan	398.55	442.90	398.55	442.90	123.92	171.79	399.66	553.68	769.07	1,065.46
Somalia	99.26	110.43	99.26	110.43	9.29	21.30	30.05	68.84	57.83	132.48
Saudi Arabia	11.57	12.36	11.57	12.36	14.65	15.66	37.33	39.91	65.56	70.09
Paraguay	29.23	29.36	29.23	29.36	37.02	37.19	101.49	101.95	195.30	196.18
Pakistan	0.21	0.27	0.21	0.27	0.23	0.32	0.59	0.81	1.04	1.43
Nigeria	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.03	0.04	0.05






Figure 2: Sensitivity of value-based maximum price to vaccine efficacy: (i) assuming treatment coverage = 0%, (ii) assuming treatment coverage = 100%

